[Effect of secretin and gabexate-mesilate (synthetic protease inhibitor) on serum amylase level after ERCP].
Complication rate of ERCP is about 2%, mortality rate 0,2%. In about 1% acute pancreatitis or recurrency of chronic pancreatitis occurs. In 20 to 73% a rise of serum amylase is noted without clinical symptoms. In a randomized trial the influence of secretin and gabexate-mesilate (synthetic protease inhibitor) on ERCP-correlated complications was analyzed. Gabexate-mesilate caused a significant decrease of ERCP-induced hyperamylasemias, whereas secretin showed no effect.
D000469:Alkaline Phosphatase / Q000097:blood; D000681:Amylases / Q000097:blood*; D002760:Cholangiopancreatography, Endoscopic Retrograde / Q000009:adverse effects; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D016670:Gabexate; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging; D010195:Pancreatitis / Q000000981:diagnostic imaging; D012633:Secretin / Q000627:therapeutic use*
D006146:Guanidines; D012633:Secretin; D016670:Gabexate; D000469:Alkaline Phosphatase; D000681:Amylases
Einfluss von Sekretin und Gabexat-mesilat (synthetischer Proteaseninhibitor) auf die Serumamylase-Spiegel nach ERCP.